Juan J Badimon

List of Publications by Year
in descending order

198	24,592	14614 66	6979 154
papers	citations	h-index	g-index

206	206	206	16626
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effects of electret coating technology on coronary stent thrombogenicity. Platelets, 2022, 33, 312-319.	1.1	3
2	Not only how much, but also how to, when measuring epicardial adipose tissue. Magnetic Resonance Imaging, 2022, 86, 149-151.	1.0	7
3	Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102417.	1.8	29
4	Perâ€Protocol Versus Intentionâ€toâ€Treat in Clinical Trials: The Example of GLOBALâ€LEADERS Trial. Journal of the American Heart Association, 2022, 11, e025561.	1.6	1
5	HDL: un nuevo biomarcador para la insuficiencia cardiaca. Revista Espanola De Cardiologia (English Ed) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	0
6	Randomized Trial of Empagliflozin in Nondiabetic Patients With HeartÂFailure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 243-255.	1.2	280
7	Reply: empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention. Expert Review of Cardiovascular Therapy, 2021, 19, 101-102.	0.6	0
8	Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic HeartÂFailure. JACC: Cardiovascular Imaging, 2021, 14, 393-407.	2.3	114
9	Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2021, 33, 33-40.	0.1	1
10	Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2021, 77, 1660-1669.	1.2	111
11	Overview of Aspirin and Platelet Biology. American Journal of Cardiology, 2021, 144, S2-S9.	0.7	22
12	Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF. JACC: Heart Failure, 2021, 9, 578-589.	1.9	118
13	Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection. Cardiovascular Drugs and Therapy, 2021, , 1.	1.3	11
14	Â¿Son los inhibidores del receptor SGLT2 fÃ¡rmacos antidiabÃ©ticos o cardiovasculares?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 33-40.	0.4	2
15	Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet thrombogenicity. Atherosclerosis, 2020, 294, 17-24.	0.4	16
16	Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy. Expert Review of Cardiovascular Therapy, 2020, 18, 635-642.	0.6	7
17	Is Increased Cardiovascular and Bleeding Risk the Price for Pain Relief?. Journal of the American College of Cardiology, 2020, 76, 530-532.	1.2	2
18	Estimation of the major cardiovascular events prevention with Inclisiran. Atherosclerosis, 2020, 313, 76-80.	0.4	19

#	Article	IF	Citations
19	Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?. Journal of Cardiovascular Pharmacology, 2020, 75, 269-275.	0.8	3
20	Duration of antiplatelet therapy after complex PCI in the TWILIGHT-COMPLEX trial: the Goldilocks dilemma. Cardiovascular Research, 2020, 116, e93-e95.	1.8	6
21	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. Journal of the American College of Cardiology, 2020, 75, 578-586.	1.2	66
22	Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance. International Journal of Molecular Sciences, 2019, 20, 3289.	1.8	37
23	Reply. Journal of the American College of Cardiology, 2019, 74, 826.	1.2	2
24	Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the â€œCardiac Benefitsâ€•of Empagliflozin Independent of its Hypoglycemic Activity?. Cardiovascular Drugs and Therapy, 2019, 33, 87-95.	1.3	51
25	Targeting thrombogenicity and inflammation in chronic HIV infection. Science Advances, 2019, 5, eaav5463.	4.7	21
26	Incremental effects of diabetes mellitus and chronic kidney disease in medial arterial calcification: Synergistic pathways for peripheral artery disease progression. Vascular Medicine, 2019, 24, 383-394.	0.8	12
27	Empagliflozin Ameliorates Adverse LeftÂVentricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Journal of the American College of Cardiology, 2019, 73, 1931-1944.	1.2	411
28	Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 275-285.	1.5	53
29	Idarucizumab, but not procoagulant concentrates, fully restores dabigatranâ€altered platelet and fibrin components of hemostasis. Transfusion, 2019, 59, 2436-2445.	0.8	8
30	SGLT receptors and myocardial ischaemia-reperfusion injury: inhibition of SGLT-1, SGLT-2, or both?. Cardiovascular Research, 2019, 115, 1572-1573.	1.8	7
31	Dual versus triple antithrombotic therapy: is there a role for direct oral anticoagulants in arterial thrombosis?. Drugs of Today, 2019, 55, 197.	0.7	2
32	The anti-inflammatory effects of SGLT inhibitors. Aging, 2019, 11, 5866-5867.	1.4	15
33	LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Drugs of Today, 2019, 55, 329.	0.7	0
34	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. Cardiovascular Drugs and Therapy, 2018, 32, 213-222.	1.3	40
35	Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis. Journal of Immunological Methods, 2018, 453, 11-19.	0.6	11
36	The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1287-1302.	1.5	78

#	Article	IF	Citations
37	Spark That Lights the Fire: Infection Triggers Cardiovascular Events. Journal of the American Heart Association, 2018, 7, e011175.	1.6	3
38	High-Density Lipoproteinâ€“Targeted Therapiesâ€”Not Dead Yet. JAMA Cardiology, 2018, 3, 1254.	3.0	4
39	Badimon Perfusion Chamber: An Ex Vivo Model of Thrombosis. Methods in Molecular Biology, 2018, 1816, 161-171.	0.4	22
40	Modulatory Role of Pulsatility on vonÂWillebrand Factor. Journal of the American College of Cardiology, 2018, 71, 2119-2121.	1.2	10
41	Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions. Atherosclerosis, 2017, 266, 81-86.	0.4	11
42	Characteristics of the Metabolic Syndrome in the Patients of IBERICAN Study (Identification of the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2017, 15, 431-438.	0.5	0
43	Role of Niacin in Cardiovascular Prevention: The Debate Continues. American Journal of Medicine, 2017, 130, e345.	0.6	1
44	Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	26
45	Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thrombosis and Haemostasis, 2017, 117, 1981-1988.	1.8	15
46	Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways. Thrombosis and Haemostasis, 2017, 117, 2312-2321.	1.8	8
47	Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation. PLoS ONE, 2017, 12, e0171486.	1.1	16
48	Susceptibility to chronic social stress increases plaque progression, vulnerability and platelet activation. Thrombosis and Haemostasis, 2017, 117, 816-818.	1.8	13
49	Niacin is still beneficial. Implications from an updated meta-regression analysis. Acta Cardiologica, 2016, 71, 463-472.	0.3	5
50	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. American Heart Journal, 2016, 182, 125-134.	1.2	108
51	Cardiac Complications After Community-Acquired Pneumonia. American Journal of Cardiology, 2016, 117, 310.	0.7	8
52	Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion. Circulation, 2016, 133, 954-966.	1.6	155
53	DenervaciÃ³n renal por catÃ©ter como tratamiento para la hipertensiÃ³n pulmonar: Â¿esperanza o espejismo?. Revista Espanola De Cardiologia, 2015, 68, 551-553.	0.6	5
54	Catheter-based Renal Denervation as a Treatment for Pulmonary Hypertension: Hope or Hype?. Revista Espanola De Cardiologia (English Ed), 2015, 68, 551-553.	0.4	6

#	Article	IF	Citations
55	Reply. Journal of the American College of Cardiology, 2015, 65, 1490-1491.	1.2	1
56	HDL Dysfunction. Journal of the American College of Cardiology, 2015, 66, 1486-1488.	1.2	15
57	Beginning to Understand High-Density Lipoproteins. Endocrinology and Metabolism Clinics of North America, 2014, 43, 913-947.	1.2	85
58	Pathophysiology of Acute Coronary Syndrome. Current Atherosclerosis Reports, 2014, 16, 401.	2.0	217
59	Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. Thrombosis Research, 2014, 133, 880-885.	0.8	13
60	The Sum of Two Evils. Journal of the American College of Cardiology, 2014, 64, 1926-1928.	1.2	39
61	Alternatively Spliced Tissue Factor Promotes Plaque Angiogenesis Through the Activation of Hypoxia-Inducible Factor-1Î± and Vascular Endothelial Growth Factor Signaling. Circulation, 2014, 130, 1274-1286.	1.6	44
62	Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. Thrombosis and Haemostasis, 2014, 112, 1069-1070.	1.8	4
63	Modelos experimentales de aterosclerosis. Revista Espanola De Cardiologia Suplementos, 2013, 13, 3-12.	0.2	3
64	Macrophages Transmit Potent Proangiogenic Effects of oxLDL In Vitro and In Vivo Involving HIF-1Î± Activation: a Novel Aspect of Angiogenesis in Atherosclerosis. Journal of Cardiovascular Translational Research, 2013, 6, 558-569.	1.1	57
65	Reperfusion-triggered stress protein response in the myocardium is blocked by post-conditioning. Systems biology pathway analysis highlights the key role of the canonical aryl-hydrocarbon receptor pathway. European Heart Journal, 2013, 34, 2082-2093.	1.0	36
66	Systems Pharmacology of Adverse Event Mitigation by Drug Combinations. Science Translational Medicine, 2013, 5, 206ra140.	5.8	105
67	Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thrombosis and Haemostasis, 2013, 110, 118-123.	1.8	35
68	Accelerated Reendothelialization, Increased Neovascularization and Erythrocyte Extravasation after Arterial Injury in BAMBIâ¯/âˆ’ Mice. PLoS ONE, 2013, 8, e58550.	1.1	15
69	Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. European Heart Journal, 2012, 33, 264-273.	1.0	36
70	Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type. Atherosclerosis, 2012, 220, 72-77.	0.4	95
71	High-Density Lipoprotein and Cardiovascular Risk Reduction: Promises and Realities. Revista Espanola De Cardiologia (English Ed), 2012, 65, 305-308.	0.4	9
72	Coronary Artery Disease in Aging Women: A Menopause of Endothelial Progenitor Cells?. Medical Clinics of North America, 2012, 96, 93-102.	1.1	15

#	Article	IF	Citations
73	Papel de la proteÃna trasferidora de Ã©steres de colesterol en aterosclerosis: mÃ¡s preguntas que respuestas, mÃ¡s dudas que promesas. Revista Colombiana De Cardiologia, 2012, 19, 180-183.	0.1	0
74	LipoproteÃnas de alta densidad y reducciÃ³n de riesgo cardiovascular: Â¿promesas o realidades?. Revista Espanola De Cardiologia, 2012, 65, 305-308.	0.6	12
75	Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term. Thrombosis and Haemostasis, 2012, 108, 1246-1248.	1.8	18
76	The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion. International Journal of Cardiology, 2011, 147, 428-432.	0.8	55
77	Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. International Journal of Cardiology, 2011, 153, 256-261.	0.8	24
78	Lethal myocardial reperfusion injury: A necessary evil?. International Journal of Cardiology, 2011, 151, 3-11.	0.8	30
79	Cardiovascular implications of HIV-induced dyslipidemia. Atherosclerosis, 2011, 219, 384-389.	0.4	58
80	Adeno-associated Virus Serotype 8 ApoA-I Gene Transfer Reduces Progression of Atherosclerosis in ApoE-KO Mice: Comparison of Intramuscular and Intravenous Administration. Journal of Cardiovascular Pharmacology, 2011, 57, 325-333.	0.8	9
81	Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?. Internal and Emergency Medicine, 2011, 6, 29-34.	1.0	21
82	Experimental Models for the Investigation of High-Density Lipoproteinâ€“Mediated Cholesterol Efflux. Current Atherosclerosis Reports, 2011, 13, 266-276.	2.0	45
83	The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. Clinical Lipidology, 2011, 6, 181-208.	0.4	9
84	Particle Traps Prevent Adverse Vascular and Prothrombotic Effects of Diesel Engine Exhaust Inhalation in Men. Circulation, 2011, 123, 1721-1728.	1.6	178
85	The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMPâ€1 and MMPâ€9 in human macrophages in vitro. FASEB Journal, 2011, 25, 35-44.	0.2	81
86	Development of a preclinical model of ischemic cardiomyopathy in swine. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H530-H537.	1.5	20
87	Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood. , 2011, , 53-66.		0
88	Thrombi of Different Pathologies: Implications for Diagnosis and Treatment. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 274-291.	0.4	51
89	Prostanoid and TP-receptors in atherothrombosis: Is there a role for their antagonism?. Thrombosis and Haemostasis, 2010, 104, 949-954.	1.8	35
90	A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel in a randomised phase I study. Thrombosis and Haemostasis, 2010, 103, 205-212.	1.8	25

#	Article	IF	Citations
91	Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgeryâ˜†â˜†â˜†. Interactive Cardiovascular and Thoracic Surgery, 2010, 10, 863-867.	0.5	27
92	Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. European Heart Journal, 2010, 31, 1573-1582.	1.0	74
93	Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. European Heart Journal, 2010, 31, 2049-2057.	1.0	56
94	Contrast-Enhanced Ultrasound Imaging Detects Intraplaque Neovascularization in an Experimental Model of Atherosclerosis. JACC: Cardiovascular Imaging, 2010, 3, 1256-1264.	2.3	44
95	Increasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease. Revista Espanola De Cardiologia (English Ed), 2010, 63, 323-333.	0.4	8
96	Incremento de las HDL como arma terapÃ©utica en la aterotrombosis. Revista Espanola De Cardiologia, 2010, 63, 323-333.	0.6	18
97	Platelet reactivity and nonresponse to dual antiplatelet therapy: A review. Platelets, 2009, 20, 531-538.	1.1	13
98	Upâ€regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoAâ€‹_{Milano}. Journal of Cellular and Molecular Medicine, 2009, 13, 3226-3235.	1.6	46
99	In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. International Journal of Cardiovascular Imaging, 2009, 25, 251-257.	0.7	40
100	Diagnosis of Atherosclerosis by Imaging. American Journal of Medicine, 2009, 122, S15-S25.	0.6	54
101	Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. Atherosclerosis, 2009, 202, 185-191.	0.4	19
102	Genesis and Dynamics of Atherosclerotic Lesions: Implications for Early Detection. Cerebrovascular Diseases, 2009, 27, 38-47.	0.8	55
103	Safe and Sustained Overexpression of Functional Apolipoprotein A-I/High-density Lipoprotein in Apolipoprotein A-Iâ€“null Mice by Muscular Adeno-associated Viral Serotype 8 Vector Gene Transfer. Journal of Cardiovascular Pharmacology, 2009, 54, 405-411.	0.8	10
104	HDL-cholesterol: Is it really good?. Biochemical Pharmacology, 2008, 76, 443-452.	2.0	41
105	Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration. Journal of the American College of Cardiology, 2008, 51, 1104-1109.	1.2	122
106	Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis, 2008, 201, 76-84.	0.4	20
107	Diesel exhaust inhalation increases thrombus formation in man. European Heart Journal, 2008, 29, 3043-3051.	1.0	271
108	Clinical implications of clopidogrel resistance. Thrombosis and Haemostasis, 2008, 100, 196-203.	1.8	79

#	Article	IF	Citations
109	Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thrombosis and Haemostasis, 2008, 100, 76-82.	1.8	84
110	Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions. Clinical Medicine Cardiology, 2008, 2, CMC.S642.	0.1	3
111	TF Independent Potentiation of FVIIa Activity in CAD Plasma: An Assessment Using Two Chromogenic Assays.. Blood, 2008, 112, 1820-1820.	0.6	0
112	Validation Study of a Semi-Automated Program for Quantification of Atherosclerotic Burden. Journal of Cardiovascular Magnetic Resonance, 2007, 9, 615-620.	1.6	10
113	Statin Therapy Alone and in Combination with an Acyl-CoA:Cholesterol <i>O</i>-Acyltransferase Inhibitor on Experimental Atherosclerosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 9-17.	0.5	10
114	Early Metoprolol Administration Before Coronary Reperfusion Results in Increased Myocardial Salvage. Circulation, 2007, 115, 2909-2916.	1.6	142
115	Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: In vivo demonstration by high-resolution MRI. Atherosclerosis, 2007, 190, 106-113.	0.4	48
116	Novel Imaging Techniques for Quantifying Overall Atherosclerotic Burden. Revista Espanola De Cardiologia (English Ed), 2007, 60, 299-309.	0.4	8
117	Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thrombosis and Haemostasis, 2007, 98, 883-888.	1.8	123
118	Dual antiplatelet therapy and drug eluting stents: a marriage of convenience. Thrombosis Journal, 2007, 5, 15.	0.9	4
119	Comparison of Platelet Function and Morphology in Patients Undergoing Percutaneous Coronary Intervention Receiving Bivalirudin Versus Unfractionated Heparin Versus Clopidogrel Pretreatment and Bivalirudin. American Journal of Cardiology, 2007, 100, 417-424.	0.7	58
120	Platelets and the vulnerable plaque. , 2007, , 39-51.		0
121	The development of endotension is associated with increased transmission of pressure and serous components in porous expanded polytetrafluoroethylene stent-grafts: Characterization using a canine model. Journal of Vascular Surgery, 2006, 43, 109-116.	0.6	46
122	Pathogenesis of Atherosclerosis. , 2006, , 49-85.		0
123	Reduced Acute Vascular Injury and Atherosclerosis in Hyperlipidemic Mice Transgenic for Lysozyme. American Journal of Pathology, 2006, 169, 303-313.	1.9	22
124	Measures of Thrombosis and Fibrinolysis. Clinics in Laboratory Medicine, 2006, 26, 655-678.	0.7	7
125	Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients. Thrombosis and Haemostasis, 2006, 95, 441-446.	1.8	18
126	Pharmacology of thienopyridines: rationale for dual pathway inhibition. Country Review Ukraine, 2006, 8, G3-G9.	0.8	20

#	Article	IF	Citations
127	Ezetimibe: one step beyond in the battle against atherosclerosis. Future Lipidology, 2006, 1, 255-266.	0.5	2
128	Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nuclear Medicine, 2006, 6, 3.	1.4	112
129	From Vulnerable Plaque to Vulnerable Patientâ€"Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report. American Journal of Cardiology, 2006, 98, 2-15.	0.7	594
130	Chronic Thrombus Detection With In Vivo Magnetic Resonance Imaging and a Fibrin-Targeted Contrast Agent. Circulation, 2005, 112, 1594-1600.	1.6	150
131	Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and compositionâ€"a magnetic resonance imaging study. European Heart Journal, 2005, 26, 1557-1561.	1.0	91
132	Thrombin/inflammation paradigms: A closer look at arterial and venous thrombosis. American Heart Journal, 2005, 149, S19-S31.	1.2	27
133	Does shear stress modulate both plaque progression and regression in the thoracic aorta?. Journal of the American College of Cardiology, 2005, 45, 846-854.	1.2	127
134	Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Simvastatin on Human Atherosclerotic Lesions. Journal of the American College of Cardiology, 2005, 46, 106-112.	1.2	257
135	Atherothrombosis and High-Risk Plaque. Journal of the American College of Cardiology, 2005, 46, 937-954.	1.2	666
136	Atherothrombosis and High-Risk Plaque. Journal of the American College of Cardiology, 2005, 46, 1209-1218.	1.2	157
137	Peroxisome proliferator-activated receptor ligands in atherosclerosis. Expert Opinion on Investigational Drugs, 2004, 13, 1393-1403.	1.9	8
138	In Vivo 16-Slice, Multidetector-Row Computed Tomography for the Assessment of Experimental Atherosclerosis. Circulation, 2004, 110, 1467-1472.	1.6	64
139	Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences*1. European Heart Journal, 2004, 25, 1197-1207.	1.0	240
140	Tissue Factor Coagulation Pathway: A New Therapeutic Target in Atherothrombosis. Journal of Cardiovascular Pharmacology, 2004, 43, 669-676.	0.8	29
141	Caspase-3 and Tissue Factor Expression in Lipid-Rich Plaque Macrophages. Circulation, 2004, 109, 2001-2008.	1.6	115
142	Plaque Neovascularization Is Increased in Ruptured Atherosclerotic Lesions of Human Aorta. Circulation, 2004, 110, 2032-2038.	1.6	607
143	Evolving Concepts in the Triad of Atherosclerosis, Inflammation and Thrombosis. Journal of Thrombosis and Thrombolysis, 2004, 17, 35-44.	1.0	123
144	Clinical and Experimental Experience with Factor Xa Inhibitors. American Journal of Cardiovascular Drugs, 2004, 4, 379-384.	1.0	13

#	Article	IF	Citations
145	The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis. Journal of the American College of Cardiology, 2004, 43, 464-473.	1.2	99
146	Shear stress-dependent platelet function after LDL cholesterol apheresis. Thrombosis Research, 2004, 113, 395-398.	0.8	15
147	Atherothrombosis: the role of tissue factor. International Journal of Biochemistry and Cell Biology, 2004, 36, 25-30.	1.2	23
148	Magnetic Resonance Imaging of High- Risk Plaque. , 2004, , 101-128.		0
149	Pathogenetic concepts of acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, S7-S14.	1.2	143
150	Benefits and Risks of Simvastatin in Patients with Familial Hypercholesterolaemia. Drug Safety, 2003, 26, 769-786.	1.4	5
151	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1664-1672.	1.6	2,308
152	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1772-1778.	1.6	1,562
153	Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity. Circulation, 2003, 107, 973-977.	1.6	277
154	A Novel Nonobstructive Intravascular MRI Coil. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 346-350.	1.1	50
155	Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. Current Opinion in Cardiology, 2003, 18, 286-294.	0.8	22
156	Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thrombosis and Haemostasis, 2003, 90, 377-384.	1.8	150
157	Diagnosis of Isolated Noncompaction of the Myocardium by Magnetic Resonance Imaging. Circulation, 2002, 105, .	1.6	32
158	Can We Image the â€œActiveâ€•Thrombus?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1753-1754.	1.1	10
159	Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions. Circulation, 2002, 106, 2884-2887.	1.6	467
160	Progression and Regression of Atherosclerotic Lesions. Circulation, 2002, 105, 993-998.	1.6	180
161	The Mikamo Lecture 2002. Therapeutic Targets for the Treatment of Atherothrombosis in the New Millennium-Clinical Frontiers in Atherosclerosis Research.. Circulation Journal, 2002, 66, 783-790.	0.7	21
162	MRI and Characterization of Atherosclerotic Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1065-1074.	1.1	138

#	Article	IF	Citations
163	In vivo noninvasive detection and age definition of arterial thrombus by MRI. Journal of the American College of Cardiology, 2002, 39, 1366-1373.	1.2	115
164	Antithrombotic Effects of DX-9065a, a Direct Factor Xa Inhibitor. Thrombosis and Haemostasis, 2002, 88, 733-738.	1.8	35
165	Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thrombosis and Haemostasis, 2002, 88, 733-8.	1.8	8
166	Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. Journal of the American College of Cardiology, 2001, 37, 1149-1154.	1.2	102
167	Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. Journal of the American College of Cardiology, 2001, 38, 1307-1312.	1.2	150
168	Value or desirability of hemorheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials. Current Opinion in Lipidology, 2001, 12, 629-637.	1.2	19
169	Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences. Annals of Internal Medicine, 2001, 134, 224.	2.0	253
170	Effect of p27 Deficiency and Rapamycin on Intimal Hyperplasia: In Vivo and In Vitro Studies Using a p27 Knockout Mouse Model. Laboratory Investigation, 2001, 81, 895-903.	1.7	61
171	Effects of Lipid-Lowering by Simvastatin on Human Atherosclerotic Lesions. Circulation, 2001, 104, 249-252.	1.6	476
172	Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice. Circulation, 2001, 103, 2604-2609.	1.6	112
173	Artery Dissection and Arterial Thrombus Aging. Circulation, 2001, 103, 2420-2421.	1.6	19
174	New Understanding of Atherosclerosis (Clinically and Experimentally) with Evolving MRI Technology in Vivo. Annals of the New York Academy of Sciences, 2001, 947, 181-198.	1.8	61
175	Antithrombotic effects of Abciximab. American Journal of Cardiology, 2000, 85, 1167-1172.	0.7	36
176	Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. American Journal of Cardiology, 2000, 86, 246-249.	0.7	49
177	Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood, 2000, 96, 170-175.	0.6	385
178	Intimal Tissue Factor Activity Is Released from the Arterial Wall after Injury. Thrombosis and Haemostasis, 2000, 83, 622-628.	1.8	32
179	Serial In Vivo MRI Documents Arterial Remodeling in Experimental Atherosclerosis. Circulation, 2000, 101, 586-589.	1.6	137
180	Mouse Model of Femoral Artery Denudation Injury Associated With the Rapid Accumulation of Adhesion Molecules on the Luminal Surface and Recruitment of Neutrophils. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 335-342.	1.1	201

#	Article	IF	Citations
181	Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2316-2321.	1.1	79
182	Noninvasive In Vivo Human Coronary Artery Lumen and Wall Imaging Using Black-Blood Magnetic Resonance Imaging. Circulation, 2000, 102, 506-510.	1.6	561
183	In Vivo Magnetic Resonance Evaluation of Atherosclerotic Plaques in the Human Thoracic Aorta. Circulation, 2000, 101, 2503-2509.	1.6	316
184	Noninvasive In Vivo Magnetic Resonance Imaging of Experimental Coronary Artery Lesions in a Porcine Model. Circulation, 2000, 101, 2956-2961.	1.6	102
185	High resolution ex vivo magnetic resonance imaging of in situ coronary and aortic atherosclerotic plaque in a porcine model. Atherosclerosis, 2000, 150, 321-329.	0.4	95
186	Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. Journal of the American College of Cardiology, 2000, 36, 2303-2310.	1.2	74
187	Local Inhibition of Tissue Factor Reduces the Thrombogenicity of Disrupted Human Atherosclerotic Plaques. Circulation, 1999, 99, 1780-1787.	1.6	250
188	The Diagnostic Accuracy of Ex Vivo MRI for Human Atherosclerotic Plaque Characterization. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2756-2761.	1.1	302
189	Acute coronary syndromes: biology. Lancet, The, 1999, 353, s5-s9.	6.3	215
190	Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. Journal of the American College of Cardiology, 1999, 33, 1294-1304.	1.2	184
191	Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening. Atherosclerosis, 1998, 140, 307-314.	0.4	47
192	Noninvasive In Vivo High-Resolution Magnetic Resonance Imaging of Atherosclerotic Lesions in Genetically Engineered Mice. Circulation, 1998, 98, 1541-1547.	1.6	224
193	Tissue Factor Modulates the Thrombogenicity of Human Atherosclerotic Plaques. Circulation, 1997, 95, 594-599.	1.6	475
194	Acute biological response to laser balloon angioplasty in the atherosclerotic rabbit. Lasers in Surgery and Medicine, 1994, 14, 7-12.	1.1	3
195	Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. Journal of the American College of Cardiology, 1994, 23, 1562-1569.	1.2	551
196	The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes. New England Journal of Medicine, 1992, 326, 310-318.	13.9	1,673
197	The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes. New England Journal of Medicine, 1992, 326, 242-250.	13.9	3,135
198	Quantification and immunolocalization of apolipoprotein E in experimental atherosclerosis. Atherosclerosis, 1986, 61, 57-66.	0.4	21